drugset / Trial / NCT06560138
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-4602 in subjects with HER2-expressing or HER2-mutated locally advanced or metastatic solid tumors.
Timeline
- Start
- 2025-03-01
- Primary completion
- 2025-12-14
- Completion
- 2026-09-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-4602 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | SHR-4602 | Monoclonal antibody | 2.5 mg/kg | Intravenous |
Indications
No indication recorded.